ACB — Aurora Cannabis Inc.
Aurora Cannabis Inc. is a leading company in the global cannabis industry, focusing on the cultivation, production, and sale of various cannabis and cannabis-derived products across Canada and internationally. Beyond its core product offerings, the company engages in a broad spectrum of related activities, including the design and engineering of facilities, cannabis breeding programs, research and development, and both wholesale and retail distribution channels. For medical users, Aurora provides a diverse selection of products such as different strains of dried cannabis, cannabis oils, capsules, and topical kits. Their inventory also includes ancillary items like vaporizers, vaporizer accessories, herb mills (specifically for CanniMed products), grinders, and secure containers for vaporizers. The company is actively involved in developing advanced medical cannabis products, with ongoing work on oral, topical, edible, and inhalable formulations. Furthermore, Aurora manages CanvasRX, a network of centers dedicated to cannabis counseling and community outreach. Its service portfolio extends to providing patient support, specialized design and construction services, and comprehensive analytical testing for cannabis products. Aurora Cannabis Inc. manages an extensive collection of brands, including Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. The company's main corporate office is located in Edmonton, Canada.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: CA
- Exchange: NASDAQ Global Select
- Employees: 1,073
- Website: https://www.auroramj.com
Latest SEC filings for ACB
- 6-K — 2026-10-14
- 6-K — 2026-10-08
- 6-K — 2026-09-16
- 6-K — 2026-09-14
- 6-K — 2026-09-09
- F-X — 2026-09-02
- 6-K — 2026-09-02
- 6-K — 2026-08-24
- 6-K — 2026-08-19
- 6-K — 2026-08-19
Latest ACB news
- — Should You Buy Curaleaf Stock Amid Its Hostile Bid for Aurora? (Zacks Investment Research)
- — Aurora Cannabis tells shareholders to reject Curaleaf's revised bid (seekingalpha_market)
- — Aurora Completes Major Expansion of European EU-GMP Manufacturing Facility, More Than Doubling Expected Annual Flower Output (prnewswire.com)
- — Curaleaf's Higher Aurora Bid Raises the Stakes in Cannabis Consolidation
- — Aurora Maintains Shareholder Recommendation to Take No Action at this Time as Curaleaf Has Yet to File Their Revised Hostile Bid
- — Aurora Cannabis (TSE:ACB) Shares Up 15.6% – Still a Buy?
- — Aurora Cannabis Sees Unusually High Options Volume (NASDAQ:ACB)
- — Curaleaf raises Aurora Cannabis offer by 25%
- — Comparing ProPhase Labs (NASDAQ:PRPH) and Aurora Cannabis (NASDAQ:ACB)
- — Curaleaf's Hostile Takeover Attempt of Aurora Cannabis Is Hitting Turbulence. Here's What Investors Should Watch.
Educational tool only — not investment advice.